Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.9 USD | -0.93% |
|
-10.89% | -35.64% |
Valuation
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 953.9 | 586.7 | - | - |
Enterprise Value (EV) 1 | 953.9 | 586.7 | 586.7 | 586.7 |
P/E ratio | -1.4 x | -3.09 x | -2.81 x | -3.28 x |
Yield | - | - | - | - |
Capitalization / Revenue | - | - | 471 x | 5.5 x |
EV / Revenue | - | - | 471 x | 5.5 x |
EV / EBITDA | -10,017,948 x | - | - | - |
EV / FCF | -10.7 x | -3.09 x | -2.75 x | -3.11 x |
FCF Yield | -9.38% | -32.4% | -36.3% | -32.1% |
Price to Book | - | - | - | - |
Nbr of stocks (in thousands) | 41,205 | 39,376 | - | - |
Reference price 2 | 23.15 | 14.90 | 14.90 | 14.90 |
Announcement Date | 3/21/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | 1.245 | 106.8 |
EBITDA | - | -95.22 | - | - | - |
EBIT 1 | - | -96.71 | -211.1 | -247.2 | -193.9 |
Operating Margin | - | - | - | -19,858.47% | -181.66% |
Earnings before Tax (EBT) 1 | - | -98.15 | -201 | -247.8 | -204.9 |
Net income 1 | -40.95 | -98.15 | -200.9 | -247.7 | -204.9 |
Net margin | - | - | - | -19,898.03% | -191.94% |
EPS 2 | -104.3 | -16.53 | -4.820 | -5.301 | -4.540 |
Free Cash Flow 1 | - | -89.44 | -189.9 | -213.1 | -188.5 |
FCF margin | - | - | - | -17,112.72% | -176.55% |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 9/1/23 | 3/21/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | -28.71 | -34.96 | -40.81 | -48.29 | -55.5 | -66.37 | -53.55 | -59.1 |
Operating Margin | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -35.47 | -32.08 | -35.81 | -45.92 | -53.32 | -65.58 | -53.55 | -59.1 |
Net income 1 | -35.47 | -32.08 | -35.81 | -45.92 | -53.32 | -65.58 | -53.55 | -59.1 |
Net margin | - | - | - | - | - | - | - | - |
EPS 2 | -47.37 | -1.490 | -0.8700 | -1.121 | -1.283 | -1.539 | -1.165 | -1.295 |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 12/13/23 | 3/21/24 | 5/14/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt | - | - | - | - | - |
Net Cash position | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow 1 | - | -89.4 | -190 | -213 | -188 |
ROE (net income / shareholders' equity) | - | -53% | -61.3% | -83% | - |
ROA (Net income/ Total Assets) | - | -42.4% | -51.1% | -63.5% | - |
Assets 1 | - | 231.6 | 393.3 | 390.3 | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex 1 | - | 8.28 | 6 | 6.33 | 7 |
Capex / Sales | - | - | - | 508.7% | 6.56% |
Announcement Date | 9/1/23 | 3/21/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.64% | 592M | |
+34.14% | 51.51B | |
-6.54% | 39.03B | |
+34.92% | 38.91B | |
-12.11% | 26.68B | |
+12.62% | 26.13B | |
-13.43% | 19.91B | |
+43.73% | 13.71B | |
+31.81% | 12.38B | |
-4.54% | 11.74B |
- Stock Market
- Equities
- CRGX Stock
- Financials CARGO Therapeutics, Inc.